Is Mazdutide legal in the US?
No. It is not approved in the US; it is approved in China.
Not approved by the FDA for any use. Mazdutide is approved in China, where the NMPA cleared it in June 2025 for chronic weight management in adults with overweight or obesity and in September 2025 for glycemic control in type 2 diabetes. In the US it is investigational, with Eli Lilly holding the rights, one US phase 2 trial published and no phase 3 result or FDA filing reported. 3612
No. It is approved only in China. It has been approved for weight management since June 2025 and for type 2 diabetes since September 2025. In the US it is in phase 2 trials run by Eli Lilly. 36
Not as an approved drug. It has no FDA approval and no legal US supply outside clinical trials. Products sold online are unregulated. 6
More on Mazdutide
Citations
- StatPearls: Glucagon-like peptide-1 receptor agonists ncbi.nlm.nih.gov
- JAMA 2026: Glucagon receptor agonism in obesity therapeutics doi.org
- Drugs 2025: Mazdutide, first approval doi.org
- Ji 2025, NEJM: Mazdutide in Chinese adults with overweight or obesity (GLORY-1) doi.org
- Diabetes Obes Metab 2025: Systematic review of mazdutide trials doi.org
- ClinicalTrials.gov: NCT06124807, US phase 2 trial of mazdutide clinicaltrials.gov
- Int J Mol Sci 2022: GLP-1 receptor signaling and insulin secretion doi.org
- Diabetes Obes Metab 2024: Glucagon receptor agonism and energy expenditure doi.org
- BMJ 2026: Network meta-analysis of incretin-based drugs for weight loss doi.org
- JAMA 2026: Mazdutide for weight reduction in Chinese adults with obesity (GLORY-2) pubmed.ncbi.nlm.nih.gov
- Front Endocrinol 2024: Meta-analysis of randomized trials of mazdutide doi.org
- Hsia 2026, Lancet Diabetes Endocrinol: mazdutide in US adults with obesity or overweight, phase 2 randomized placebo-controlled trial pubmed.ncbi.nlm.nih.gov
Reference information only, not medical advice. Drawn from the Mazdutide article, fact-checked against the cited sources. No dosing anywhere on this site.